NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Strand Therapeutics

Strand Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceswww.strandtx.com

Last Round

Series B

Mar 17, 2026

Est. Valuation

$550M

Total Funding Raised

$256M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Strand Therapeutics is a biotechnology company focused on developing gene therapies utilizing synthetic biology to create immunotherapies that enhance the immune system's ability to combat cancer by producing targeted cancer-killing proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

programmable mRNAmRNA therapeuticsself-replicating mRNAsaRNAgenetic circuitssolid tumor oncologycancer immunotherapyprecision oncologysynthetic biologysynbiotargeted cytokine therapyintratumoral therapydrug development platformlogic-gated therapiesclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Strand Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Strand Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Strand Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 17, 2026
Series BAug 7, 2025
Series A ExtensionNov 28, 2022
Series AJun 23, 2021
SeedJun 4, 2019

Key People

Founding team and executive leadership

Jacob Becraft

Co-Founder And CEO

Founding Team

Samta Kundu

Chief Operating Officer

Executive Team

Strand Therapeutics Investors

Notable investors and investment history

Strand Therapeutics investors
InvestorRounds
Redmile GroupSeries A
ICONIQ CapitalSeries B
Camford CapitalSeries A
Playground GlobalSeries B, Series A Extension, Series A, Seed
LG Technology VenturesSeries B
ANRI株式会社Series B, Seed, Series A
JIC Venture Growth InvestmentsSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Lead program STX-001 now in Phase 1 trial for solid tumors.

  • Aug 23, 2025

    Dr. Jason J. Luke appointed as new Chief Medical Officer.

Strand Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Strand Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Strand Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range123
Year Founded2017
Last FundingMar 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.